The first batch of Covovax is being manufactured at the Serum Institute of India's Pune facility, SII CEO Adar Poonawalla said on Friday. Image credits: Twitter @SerumInstIndia
In March, Poonawalla had said that the clinical trials of the Covovax vaccine have begun in India and the company hopes to launch it by September this year
The first batch of Covovax is being manufactured at the Serum Institute of India's Pune facility, SII CEO Adar Poonawalla said on Friday. Image credits: Twitter @SerumInstIndia
Pune: The first batch of Covovax, a vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII CEO Adar Poonawalla said on Friday.
Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing. Well done team @seruminstindia! pic.twitter.com/K4YzY6o73A
— Adar Poonawalla (@adarpoonawalla) June 25, 2021
In March this year, he had said that the clinical trials of Covovax vaccine have begun in India and the company hopes to launch it by September this year.
In August 2020, American vaccine company Novavax Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its vaccine candidate, in low and middle-income countries and India.
In January this year, the Serum Institute had rolled out Covishield vaccine in the country. It had entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.